Updated:
CODA Biotherapeutics
CODA Biotherapeutics is a preclinical-stage biopharmaceutical company developing a chemogenetic gene therapy platform. The platform controls neuronal activity...
CODA Biotherapeutics
CODA Biotherapeutics is a preclinical-stage biopharmaceutical company developing a chemogenetic gene therapy platform. The platform controls neuronal activity to treat intractable diseases by modifying target populations with gene therapy. This involves expressing a tunable ligand-gated ion channel in neurons that responds to a proprietary small molecule.
General information
Firm type
Asset Manager
Location
Region
North America
Country
United States
City
South San Francisco
Corporate office
South San Francisco, CA, United States
Sector focus
Frequently asked questions
Who makes investment decisions at CODA Biotherapeutics?
Public records do not identify any named principals or investment decision-makers at CODA Biotherapeutics. The firm has not disclosed a CEO, CIO, or founding team. This lack of public leadership information is unusual for a biotech firm and may indicate a very early stage of public presence or a deliberate privacy posture (per public record, 2026).
What stage of development is CODA Biotherapeutics' pipeline in?
The company's therapeutic programs appear to be preclinical, according to its website and sparse public filings. No clinical trials or approved therapies have been publicly listed. This suggests the firm is still in research and early animal model testing phases.
Does CODA Biotherapeutics invest in external funds or only direct projects?
CODA Biotherapeutics appears to be a biotechnology company developing its own proprietary drug candidates, not an investment firm. There is no evidence it invests in external funds or makes direct co-investments alongside other parties. Its operations are consistent with a drug developer, not an allocator of capital.
Which therapeutic areas does CODA Biotherapeutics focus on?
The company targets genetic and cellular therapies, specifically in vivo gene modulation. This addresses a range of serious diseases, potentially including rare genetic disorders. The exact disease indications have not been publicly specified.
Where does CODA Biotherapeutics source its technology or intellectual property?
No specific university partnerships or licensing agreements have been publicly disclosed. The firm likely relies on internal R&D and possibly academic collaborations common in the South San Francisco biotech ecosystem, but no names or institutions have been cited.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: